| Tuberculosis - Drug Pipeline Analysis and Market | | | | This report is built using data and information sourced |
| Forecasts to 2016 | | | | from proprietary databases, primary and secondary |
| | | | research and in house analysis by team of industry |
| Summary | | | | experts. |
| Drug Pipeline Analysis and Market Forecasts to 2016" | | | | Scope |
| is an essential source of information and analysis on | | | | The scope of the report includes: |
| the global Tuberculosis (TB) drugs market. The report | | | | - Annualized global Tuberculosis drugs market |
| identifies the key trends shaping and driving the | | | | revenue data from 2001 to 2009, forecast for seven |
| global TB market. The report also provides insight | | | | years to 2016. |
| into the prevalent competitive landscape and the | | | | - Geographies covered in this report include the US |
| emerging players expected to significantly alter the | | | | (United States), the UK (United Kingdom), Italy, Spain, |
| positioning of the existing market leaders. Most | | | | Germany, France and Japan. |
| importantly, the report provides valuable insight into | | | | - Pipeline analysis data providing a split across the |
| the pipeline products within the global TB sector. The | | | | different phases of development by mechanism of |
| global TB drugs market was worth $99m in 2009. | | | | action and emerging trends. The key classes of |
| The market is expected to decline by 2.8% during | | | | mechanism of action of drugs include ATP synthase |
| the next seven years. The TB drugs market has | | | | inhibitors, protein synthesis inhibitors, cell wall |
| been well served by antimycobacterial agents and | | | | synthesis inhibitors, DNA gyrase inhibitors, FAS |
| antibiotics since the 1960s. The cure rates have | | | | synthase inhibitors, translocase-1 inhibitors and others. |
| improved with the conventional DOTs (Directly | | | | The vaccine candidates have been segmented as |
| Observed Therapy). Multi-Drug Resistant Tuberculosis | | | | recombinant live vaccines, recombinant protein |
| (MDR-TB) has been a consequence of patient | | | | vaccines and viral vectored vaccines. |
| non-compliance and the long duration of therapy. | | | | - Analysis of the current and future market |
| Companies seem to be actively developing products | | | | competition in the global Tuberculosis drugs market. |
| for the prophylaxis and cure of TB that have lesser | | | | The key market players covered are isoniazid, |
| treatment durations. The two not-for-profit | | | | rifampin, pyrazinamide, ethambutol, streptomycin, |
| organizations, TB Alliance and the Aeras Global TB | | | | rifabutin and capreomycin. |
| Vaccine Foundation, have partnered with | | | | - Insightful review of the key industry drivers, |
| pharmaceutical players in order to address the burden | | | | restraints and challenges. Each trend is independently |
| of TB in developed and developing nations. With the | | | | researched to provide qualitative analysis of its |
| success of the ongoing clinical studies, the market is | | | | implications. |
| expected to witness a breakthrough in TB control | | | | - Key topics covered include strategic competitor |
| and treatment. The vaccines' primary focus would be | | | | assessments, market characterization, the unmet |
| to inhibit the infection at the first place. The global TB | | | | needs and the implications for the future market |
| drugs market is heading towards a phase of decline | | | | associated with TB. |
| as no launches are expected till 2016. | | | | |